BACKGROUND: Despite recent advancements in the pharmacological treatment of major depressive disorder (MDD), over half of patients who receive treatment with antidepressant medication do not achieve full remission of symptoms. There is evidence that exercise can reduce depressive symptomatology when used as a treatment for MDD. However, no randomized controlled trials have evaluated exercise as an augmentation strategy for patients with carefully diagnosed MDD who remain symptomatic following an adequate acute phase trial of antidepressant therapy. PURPOSE: TReatment with Exercise Augmentation for Depression (TREAD) is an NIMH-funded, randomized, controlled trial designed to assess the relative efficacy of two doses of aerobic exercise to augment selective serotonin reuptake inhibitor (SSRI) treatment of MDD. METHODS: The TREAD study includes 12 weeks of acute phase treatment with a 12-week post-treatment follow-up. In addition to looking at change in depressive symptoms as a primary outcome, it also includes comprehensive assessment of psychosocial function and treatment adherence. RESULTS: This paper reviews the rationale and design of TREAD and illustrates how we address several key issues in contemporary patient-oriented research on MDD: 1) the use of augmentation strategies in the treatment of depressive disorders in general, 2) the use of non-pharmacological strategies in the treatment of depressive disorders, 3) the considerations of designing a well-controlled trial using two active treatment groups, and 4) the implementation of an adherence program for the use of exercise as a treatment strategy. CONCLUSIONS: The TREAD study is uniquely designed to overcome sources of potential bias and threats to internal and external validity that have limited prior research on the mental health effects of exercise. The study is facilitated by the development of a multidisciplinary research team that includes experts in both depression treatment and exercise physiology, as well as other related fields.
RCT Entities:
BACKGROUND: Despite recent advancements in the pharmacological treatment of major depressive disorder (MDD), over half of patients who receive treatment with antidepressant medication do not achieve full remission of symptoms. There is evidence that exercise can reduce depressive symptomatology when used as a treatment for MDD. However, no randomized controlled trials have evaluated exercise as an augmentation strategy for patients with carefully diagnosed MDD who remain symptomatic following an adequate acute phase trial of antidepressant therapy. PURPOSE: TReatment with Exercise Augmentation for Depression (TREAD) is an NIMH-funded, randomized, controlled trial designed to assess the relative efficacy of two doses of aerobic exercise to augment selective serotonin reuptake inhibitor (SSRI) treatment of MDD. METHODS: The TREAD study includes 12 weeks of acute phase treatment with a 12-week post-treatment follow-up. In addition to looking at change in depressive symptoms as a primary outcome, it also includes comprehensive assessment of psychosocial function and treatment adherence. RESULTS: This paper reviews the rationale and design of TREAD and illustrates how we address several key issues in contemporary patient-oriented research on MDD: 1) the use of augmentation strategies in the treatment of depressive disorders in general, 2) the use of non-pharmacological strategies in the treatment of depressive disorders, 3) the considerations of designing a well-controlled trial using two active treatment groups, and 4) the implementation of an adherence program for the use of exercise as a treatment strategy. CONCLUSIONS: The TREAD study is uniquely designed to overcome sources of potential bias and threats to internal and external validity that have limited prior research on the mental health effects of exercise. The study is facilitated by the development of a multidisciplinary research team that includes experts in both depression treatment and exercise physiology, as well as other related fields.
Authors: Carroll W Hughes; Madhukar H Trivedi; Joseph Cleaver; Tracy L Greer; Graham J Emslie; Beth Kennard; Shauna Dorman; Tyson Bain; Judy Dubreuil; Conrad Barnes Journal: Ment Health Phys Act Date: 2009-12
Authors: Tracy L Greer; Kolette M Ring; Diane Warden; Bruce D Grannemann; Timothy S Church; Eugene Somoza; Steven N Blair; Jose Szapocznik; Mark Stoutenberg; Chad Rethorst; Robrina Walker; David W Morris; Andrzej S Kosinski; Tiffany Kyle; Bess Marcus; Becca Crowell; Neal Oden; Edward Nunes; Madhukar H Trivedi Journal: J Glob Drug Policy Pract Date: 2012
Authors: Michael W Otto; Timothy S Church; Lynette L Craft; Tracy L Greer; Jasper A J Smits; Madhukar H Trivedi Journal: Prim Care Companion J Clin Psychiatry Date: 2007
Authors: Catherine A Okoro; Georjean Stoodt; James E Rohrer; Tara W Strine; Chaoyang Li; Lina S Balluz Journal: Public Health Rep Date: 2014 Jan-Feb Impact factor: 2.792
Authors: Tracy L Greer; Joseph M Trombello; Chad D Rethorst; Thomas J Carmody; Manish K Jha; Allen Liao; Bruce D Grannemann; Heather O Chambliss; Timothy S Church; Madhukar H Trivedi Journal: Depress Anxiety Date: 2016-05-10 Impact factor: 6.505
Authors: Anisha M Suterwala; Chad D Rethorst; Thomas J Carmody; Tracy L Greer; Bruce D Grannemann; Manish Jha; Madhukar H Trivedi Journal: J Clin Psychiatry Date: 2016-08 Impact factor: 4.384